Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 166Rituximab 153Specimen Handling 111Biopsy 89Magnetic Resonance Spectroscopy 87Vincristine 85Doxorubicin 79Prednisone 78fludarabine 68venetoclax 65obinutuzumab 60ibrutinib 54Lenalidomide 53Dexamethasone 53Cytarabine 47Methotrexate 44acalabrutinib 42Etoposide 41CT-P10 39blinatumomab 38Bendamustine Hydrochloride 34fludarabine phosphate 33prednylidene 32Gemcitabine 32deltacortene 31Calcium Dobesilate 30zanubrutinib 29pembrolizumab 29glofitamab 27Nivolumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunologic Factors × Lymphoid × 90 days × Clear all
NCT05182957 2026-05-01

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
31 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡